Southwest Securities·2026-03-02 00:25Investment Rating - The report maintains a positive outlook on the innovative drug sector, highlighting multiple favorable developments and collaborations within the industry [1]. Core Insights - The innovative drug sector has seen significant collaborations, with a total business development (BD) value exceeding $50 billion in the first two months of 2026, indicating a robust growth trajectory [16]. - The report emphasizes the upcoming Q2 conferences (AACR, ELCC, ASCO, EHA) as potential catalysts for stock price increases in innovative drug companies due to expected positive data releases [16]. - The report identifies a strong performance in the medical consumables sub-sector, which has shown a 4.0% increase, while the best-performing sectors year-to-date include hospitals, medical consumables, and offline pharmacies [21][27]. Summary by Sections 1. Investment Strategy - The pharmaceutical index rose by 0.50% this week, underperforming the CSI 300 index by 0.58 percentage points, ranking 26th in industry performance [13]. - Year-to-date, the pharmaceutical sector has increased by 2.96%, outperforming the CSI 300 index by 1.21 percentage points, ranking 24th [21]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 31.06 times, with a premium of 66.99% over the entire A-share market [23]. 2. Industry and Company News - Frontier Biotech has entered a global licensing agreement with GSK for small nucleic acid drugs, with a total potential value of $963 million, including an upfront payment of $40 million [14]. - Bai Li Tianheng's dual-target antibody ADC, iza-bren, has successfully met primary endpoints in a Phase III trial for triple-negative breast cancer (TNBC), indicating significant progress in this high-risk area [15]. - The report notes that several innovative drug companies have issued profit forecasts, suggesting a sustained interest and potential growth in the sector [16]. 3. Steady Portfolio - Recommended stocks include Heng Rui Medicine (600276), Bai Jie Shen Zhou-U (688235), Yi Fan Medicine (002019), and others, indicating a diversified approach to investment in the pharmaceutical sector [16][17].